Phase 2 Waldenstrom Macroglobulinemia Clinical Trials
10 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–10 of 10 trials
Recruiting
Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
National Cancer Institute (NCI)92 enrolled125 locationsNCT04840602
Recruiting
Phase 2
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
AbbVie14 enrolled7 locationsNCT07387471
Recruiting
Phase 2
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Waldenstrom Macroglobulinemia
Massachusetts General Hospital55 enrolled5 locationsNCT06561347
Recruiting
Phase 2
Epcoritamab in Previously Treated WM
Waldenstrom MacroglobulinemiaB-Cell Lymphoproliferative Disorder
Gottfried von Keudell, MD PhD20 enrolled3 locationsNCT06510491
Recruiting
Phase 2
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
Waldenstrom MacroglobulinemiaTreatment Naive
Christian Buske80 enrolled11 locationsNCT05099471
Recruiting
Phase 2
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
Memorial Sloan Kettering Cancer Center40 enrolled8 locationsNCT07231952
Recruiting
Phase 2
Loncastuximab Tesirine in WM
Waldenstrom Macroglobulinemia
Shayna Sarosiek, MD36 enrolled4 locationsNCT05190705
Recruiting
Phase 2
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Waldenstrom Macroglobulinemia
Dana-Farber Cancer Institute42 enrolled2 locationsNCT05734495
Recruiting
Phase 2
Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM
Waldenstrom Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China42 enrolled1 locationNCT05914662
Recruiting
Phase 2Phase 3
Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
Waldenstrom Macroglobulinemia
University College, London148 enrolled25 locationsNCT04061512